Author:
Olar Adriana,Wani Khalida M.,Alfaro-Munoz Kristin D.,Heathcock Lindsey E.,van Thuijl Hinke F.,Gilbert Mark R.,Armstrong Terri S.,Sulman Erik P.,Cahill Daniel P.,Vera-Bolanos Elizabeth,Yuan Ying,Reijneveld Jaap C.,Ylstra Bauke,Wesseling Pieter,Aldape Kenneth D.
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Neurology (clinical),Pathology and Forensic Medicine
Reference73 articles.
1. Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, Dictus C, Herold-Mende C, Capper D, Unterberg A, von Deimling A, Wick W, Hartmann C (2012) No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol. doi: 10.1007/s11060-012-0863-y
2. Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131(2):242–251. doi:10.1043/1543-2165(2007)131[242:CAOQLA]2.0.CO;2
3. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, MacDonald D, Stitt L, Cairncross JG (1999) Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45(4):923–929
4. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, Cahill DP (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-oncology 16(1):81–91. doi: 10.1093/neuonc/not159
5. Cai J, Yang P, Zhang C, Zhang W, Liu Y, Bao Z, Liu X, Du W, Wang H, Jiang T, Jiang C (2014) ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples. Oncotarget 5(9):2551–2561
Cited by
280 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献